Proposed new drug law may still have flaws
The centre-state power equation works well in theory, as a system of checks and balances. But practice has been anything but…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Editor’s note
In search of consistent quality
Global regulators question perfection, look for the right approach to quality and to understand how a company responds to issues…
Exploring synergies and de-risking strategies
Even as pharma companies continue the long-term process of reducing dependence on outside sources for key input materials,…
Why Mankind Pharma’s IPO could be a milestone
While Mankind Pharma’s IPO re-validates the long-term potential of the India Pharma Inc narrative, it won’t take much for the…
Will online pharmacies blink off in India?
Tougher regulation, tighter rules, weeding out unscrupulous online pharmacies will ultimately serve the Indian patient better and…
Top of ANDA approvals list, low on IP index
India's dominance of ANDA approvals juxtaposed with the continued low ranking in the US Chamber of Commerce’s International IP…
Fix quality issues, the rest will fall in place
As policymakers strive to link budgetary allocations to better quality compliance, with stricter oversight?
Immunising India’s pharma supply chain
With China battling another COVID wave, have previous supply shocks helped immunise India's pharma procurement systems?
Why a National Drugs Database is important
The question remains, what are the plans to enforce such regulations more stringently?
Need for introspection beyond brand-building
Because laws are only as good as their enforcement
API manufacturing finally getting the attention it deserves
While formulation generics flounders a bit, the data show that the Indian API industry has done better, with a five-year revenue…
Will FMRAI’s PIL finally prod govt to make UCPMP mandatory?
As COVID-19 continues to extract its price, will a more aware patient pool build up public opinion and turn the tide?
High expectations from the draft Bill
The regulation of all retail channels as proposed by the draft Drugs, Medical Devices and Cosmetics Bill 2022 becomes even more…
India’s medicine watchdog under the scanner once again
Hopefully, this case will initiate as deep a clean up and introspection as the 2012 PCC report
Preparing for surprise inspections
Will surprise site inspections be the end of a long wait? Or the start of another tunnel into noncompliance?
Taking India beyond ‘Pharmacy of the World’
A policy to incentivise pharma R&D is crucial as there are already signs that pharma R&D dives when revenues dip
Will a limited vaccine waiver limit future options?
As attempts to ring-fence markets and restrict access continue, will India and South Africa toe the WTO line?
Still tripping on TRIPS
If India, one of the main proponents of the TRIPS waiver, is left out, is it time for an ‘India waiver’ to show the way forward?
Filling the gaps in India’s pharma manufacturing supply chain
The lessons of the past – of spiralling API costs, overdependence on a shrinking list of API makers – have been well learnt
Why we need an Aatmanirbhar booster strategy
An Aatmanirbhar booster strategy will save lives. As a bonus, it will also boost long term development programmes at local…